NCT06872125Phase 3Active not recruiting

A Double-blind Study Evaluating the Efficacy, Safety, and Tolerability of Zorevunersen in Patients With Dravet Syndrome

Study sponsor: Stoke Therapeutics, Inc · STOK

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-03Estimated
Enrollment · participants170Estimated
Source updated2026-10-20Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Recruitment status changed

Before: Recruiting. After: Active not recruiting.

Check registry source

· 1 field changed

Planned enrollment increased by 20 participants

Before: 150 participants (planned). After: 170 participants (planned).

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview